Erector Spinae Plane Block Combined With Local Infiltration Analgesia for Posterior Lumbar Interbody Fusion: Prospective, Double-Blind, Randomized Controlled Trial
In brief
Adding wound anesthetic to a nerve block improves early pain after lumbar fusion
In a randomized trial of 182 adults, combining an erector spinae plane block with local wound anesthetic reduced postoperative sufentanil use and pump activations and delayed the first request for extra pain medicine. The short-term benefit did not come with more adverse events, but the combination showed no consistent synergy, and pain and function were similar across groups at 3 months.
- Journal
- Neurospine (Q1)
- Published
- 31 October 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Meng-Yu Fu, Feng Zhao, Yi-Heng Song, Rao-Rao Zhou, Wei-Ping Ren, Yu-Kai Liang, et al.
- PMID
- 43000795
- DOI
- 10.14245/ns.26520656.0328
Why clinicians should know about it
- Picked for Spine Surgery (top studies of the week, 15 November 2026): Randomized analgesia trial in patients undergoing lumbar fusion
- Picked for Anesthesiology and Pain Medicine (paper of the day, 11 November 2026): Combined ESPB with LIA improved postoperative analgesia
Abstract
OBJECTIVE: To evaluate whether erector spinae plane block (ESPB) combined with local infiltration analgesia (LIA) provides better postoperative analgesia than ESPB alone, LIA alone, or placebo in patients undergoing posterior lumbar interbody fusion (PLIF). METHODS: This prospective, double-blind, randomized controlled trial enrolled adults undergoing open PLIF for degenerative lumbar disease. Patients were randomly assigned in a 1:1:1:1 ratio to placebo, LIA, ESPB, or combined ESPB with LIA. Fluoroscopy-guided ESPB or placebo injection was performed before induction of general anesthesia, while LIA or placebo infiltration was given before wound closure. All patients received standardized general anesthesia and postoperative patient-controlled intravenous analgesia. The primary outcomes were postoperative sufentanil consumption and visual analogue scale (VAS) pain scores at rest and during movement at 4, 8, 12, 24, and 48 hours. Analyses were based on the modified intention-to-treat population. Longitudinal VAS trajectories were assessed using linear mixed-effects models, together with multiplicity-adjusted pairwise comparisons and factorial interaction analyses. A right-censoring sensitivity analysis of time to first patient-controlled intravenous analgesia (PCIA) bolus was performed using Kaplan-Meier, log-rank, and adjusted Cox proportional hazards analyses. RESULTS: Of the 188 randomized patients, 182 were included in the modified intention-to-treat analysis. Baseline characteristics were similar across the 4 groups. Body-weight- and operative-time-normalized remifentanil and propofol consumption rates were lower in the ESPB-containing groups, whereas the rocuronium consumption rate did not differ significantly among groups. Linear mixed-effects models showed significant group×time interactions for both resting and movement VAS scores, indicating different postoperative pain trajectories among the groups. The combined ESPB with LIA group showed the most consistent short-term analgesic benefit, with lower pain scores at several early postoperative time points, lower postoperative sufentanil consumption, fewer analgesia pump activations, and a longer time to first PCIA bolus. After multiplicity adjustment, the postoperative rescue analgesia count was also lower in the combined group than in the control group. Factorial analyses identified a greater-than-additive effect only for time to first PCIA bolus, whereas the other analgesic outcomes showed no consistent evidence of statistical synergy. Right-censoring sensitivity analyses supported the longer time to first PCIA bolus in the combined group. Adverse-event rates were similar among the 4 groups, and no significant between-group differences were observed in VAS or Oswestry Disability Index scores at 3 months. CONCLUSION: Fluoroscopy-guided ESPB combined with LIA improved short-term postoperative analgesia after open PLIF. The combined regimen reduced postoperative opioid requirements and analgesia pump activations and prolonged the time to first PCIA bolus without increasing adverse events. Its benefit is better interpreted as an incremental, layered multimodal analgesic effect rather than a consistently synergistic effect across outcomes. No between-group differences in pain or functional outcomes were observed at 3 months.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.